Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. (August 2019)

Record Type:
Journal Article
Title:
Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. (August 2019)
Main Title:
Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
Authors:
Stein, E.
Toth, P.
Butcher, M.B.
Kereiakes, D.
Magnu, P.
Bays, H.
Zhou, R.
Turner, T.A.
Abstract:
Is Part Of:
Atherosclerosis. Volume 287(2019)
Journal:
Atherosclerosis
Issue:
Volume 287(2019)
Issue Display:
Volume 287, Issue 2019 (2019)
Year:
2019
Volume:
287
Issue:
2019
Issue Sort Value:
2019-0287-2019-0000
Page Start:
e7
Page End:
Publication Date:
2019-08
Subjects:
Arteriosclerosis -- Periodicals
Electronic journals
616.136
Journal URLs:
http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/j.atherosclerosis.2019.06.019 ↗
Languages:
English
ISSNs:
0021-9150
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
16401.xml